SEC Form 4 · accession 0000899243-17-011717
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Youssef El Zein
Director · 10% Owner
Pillar Pharmaceuticals I LP
Director · 10% Owner
Pillar Invest Corp
Director · 10% Owner
Pillar Pharmaceuticals II, L.P.
Director · 10% Owner
Period of report
May 1, 2017
Accepted (ET)
May 3, 2017 · 7:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F5 | May 1, 2017 | S | 41,578 | $2.2591 | D | 0 | I | See footnotes |
| Common StockF1,F2,F4,F5 | May 1, 2017 | S | 409,237 | $2.2591 | D | 0 | I | See footnotes |
| Common StockF6,F5 | May 1, 2017 | X | 409,237 | $0.00 | A | 0 | I | See footnotes |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF5,F6 | $0.70 | May 1, 2017 | X | 409,237 | D | Nov 9, 2012 | Nov 9, 2017 | Common Stock | 409,237 | 4,624,824 | I |
Explanation of responses
- F1The sales reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Persons.
- F2The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $2.25-$2.355. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. As of the date hereof, Pillar I owns directly 2,090,125 shares of common stock of the Issuer.
- F4Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. As of the date hereof, Pillar II owns directly 6,135,132 shares of common stock of the Issuer.
- F5Youssef El Zein is a director and controlling stockholder of Pillar GP and serves as the representative of a Pillar I, Pillar II and Pillar GP on the Issuer's board of directors. Mr. El Zein disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and Pillar II and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. El Zein owns directly 528,538 shares of common stock of the Issuer.
- F6Warrants beneficially owned and exercised for shares of common stock by Pillar II. Pillar GP disclaims Section 16 beneficial ownership of the Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein.